US/UK/Canada

Share

About Us

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.

Contacts

  • Visiting address

    Norra Stationsgatan 93A, Stockholm


    +46 8 697 20 00
  • Gerard Tobin

    Head of Investor Relations


    • Quotes

    The positive pozdeutinurad readout in gout is a key milestone that highlights its potential in gout treatment, supports our upcoming launch trajectory, and reinforces confidence in continued progress through 2026 and beyond.
    Guido Oelkers, President & CEO
    We started 2026 with a strong business performance driven by the continued launch success of Altuvoct and Gamifant. Additionally, we made significant advances with our pipeline with the launch of Aspaveli in C3G and IC-MPGN, and the filing of Tryngolza in sHTG in Europe.
    Guido Oelkers, President & CEO
    We have delivered significant results in the business in 2025 and importantly made tremendous progress with our pipeline setting Sobi up for significant longer term growth potential. We look forward with excitement to bringing these medicines to more and more people in need of innovative treatments.
    Guido Oelkers, President & CEO
    We delivered strong quarterly results and achieved 16 per cent revenue growth at CER demonstrating the strength of our portfolio. In 2025, we made significant advances with our pipeline, highlighted by the regulatory submissions of Aspaveli, and NASP, the pivotal read out of Tryngolza in sHTG and the agreement to acquire Arthrosi Therapeutics in order to strengthen our gout franchise.
    Guido Oelkers, President & CEO
    For the quarter, our business accelerated and achieved 21 per cent growth at CER demonstrating the strength of our portfolio. We also advanced our pipeline with the US filing acceptance for NASP in uncontrolled gout and the preparations for a new opportunity for olezarsen in severe hypertriglyceridemia, both expected to contribute significantly to long-term growth.
    Guido Oelkers, President & CEO
    Pick a time period -
    Tags ( Active)

    Sobi Q2 2026 report: Significant growth with important pipeline progress

    Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter of 2026.Second Quarter 2026   •          Total revenue increased 29 per cent at CER (constant exchange rates), 27 per cent at actual rates, to SEK 7,842 M (6,175) •          Haematology revenue increased 27 per cent at CER to SEK 5,726 M (4,570), mainly driven by strong sales of Altuvoct of SEK 1,554 M (627) and of Doptelet of SEK 1,628 M (1,220) •          Immunology revenue increased 37 per cent at CER to SEK 1,711 M (1,288), driven by strong sales of Gamifant of SEK 794 M (632) and

    The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under an incentive programme

    The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme for permanent employees (the All Employee Programme) resolved by the Annual General Meeting – on a directed share issue of no more than 223,677 redeemable and convertible class C shares.The Annual General Meeting also resolved to authorise the Board of Directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase

    Invitation: Sobi's Q2 2026 report

    Sobi plans to publish its report for the second quarter of 2026 on 16 July 2026 at 08:00 CEST.Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00 BST, and 08:00 EDT. The call will include a presentation of the results and a Q&A session.   The presentation can be followed live here  or afterwards on sobi.com . The slides will be made available on sobi.com  before the conference call.   To participate in the

    Sobi to showcase new data across haemophilia portfolio at ISTH 2026

    New analyses and real-world evidence highlight outcomes with Altuvoct®, Elocta® and Alprolix® in haemophilia A and B   Sobi® today announced new data across its haemophilia portfolio will be presented at the 2026 Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Paris, from 11–15 July 2026. Presentations include new analyses and real-world evidence evaluating treatment outcomes with Altuvoct, Elocta and Alprolix in people living with haemophilia A and B.   The data being presented include oral and poster presentations evaluating joint

    Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

    The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical safety or efficacy concerns were identified that impact approvability   Sobi to meet with FDA to discuss next steps for resubmission   Sobi® (STO: SOBI) today announced that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) for NASP (nanoencapsulated sirolimus plus pegadricase) for the treatment of adult patients with uncontrolled

    Sobi to present new clinical and real-world data at EHA 2026 in Stockholm

    Sobi’s presentations highlight research across multiple rare diseases in haematology including PNH, ITP, HLH and myelofibrosis.   Sobi® (STO: SOBI) today announced that new clinical and real-world data will be presented at the 2026 Congress of the European Hematology Association (EHA2026), taking place June 11–14 in Stockholm, Sweden. The presentations include data across paroxysmal nocturnal haemoglobinuria (PNH), immune thrombocytopenia (ITP), primary haemophagocytic lymphohistiocytosis (HLH), and myelofibrosis.   The data include real-world evidence and post hoc analyses for

    Sobi to present new data on pegcetacoplan at ERA 2026

    Sobi® today announced that new data from the pegcetacoplan clinical development programme and related research in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) will be presented at the 63rd Congress of the European Renal Association (ERA), taking place from 3 - 6 June 2026 in Glasgow, UK. Presentations will be made in collaboration with Apellis Pharmaceuticals (now part of Biogen).   The presentations include new analyses from the pivotal Phase 3 VALIANT study and its long-term extension VALE study evaluating pegcetacoplan in

    New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia

    Sobi® (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza® (olezarsen) reduced the relative risk of acute pancreatitis events by 85% (P<0.001) and reduced triglycerides by 66% in patients with severe hypertriglyceridemia (sHTG) after six months.[1]   The pooled subgroup analysis, presented as a late breaking abstract at the European Atherosclerosis Society (EAS) 2026 Congress in Athens, Greece, included 455 patients with baseline triglycerides of ≥880 mg/dL (~10 mmol/L), defined by the EAS as severe

    Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

    Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo   Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studies   Sobi® (STO: SOBI) today announced positive topline results from the pivotal Phase 3 REDUCE 2 study (NCT06439602 ) evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with

    Bulletin from Sobi’s Annual General Meeting (AGM)

    The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 6 May 2026. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:Adoption of the profit and loss statements and balance sheet and discharge of liability The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits.   The Board members and the chief executive officer were discharged from liability for the financial year 2025.   Election of Board of Directors, remuneration to the Directors, election of

    Sobi Q1 2026 report: Strong execution and pipeline momentum

    Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2026.First Quarter 2026 •          Total revenue increased 24 per cent at CER (constant exchange rates), 11 per cent at actual rates, to SEK 7,184 M (6,465) •         Haematology revenue increased 24 per cent at CER to SEK 5,186 M (4,632), mainly driven by strong sales of Altuvoct of SEK 1,240 M (455) and of Doptelet of SEK 1,433 M (1,129) •         Immunology revenue increased 24 per cent at CER to SEK 1,643 M (1,526), driven by strong sales of Gamifant of SEK 734 M (582) and Kineret of

    Invitation: Sobi's Q1 2026 report

    Sobi plans to publish its report for the first quarter of 2026 on 28 April 2026 at 08:00 CEST.Investors, analysts, and the media are invited to a conference call on the same day at 12:30 CEST, 11:30 BST, and 06:30 EDT. The call will include a presentation of the results and a Q&A session.   The presentation can be followed live here  or afterwards on sobi.com . The slides will be made available on sobi.com  before the conference call.   To participate in the

    Sobi publishes Annual and Sustainability Report for 2025

    Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for 2025, outlining the company’s progress in unlocking the potential of breakthrough innovations and therapies for people living with rare diseases.Sobi has a strong focus on building a sustainable business through collaboration and scientific expertise, ensuring that everyone eligible within its therapeutic areas has access to approved medicines. In 2025, over 53,000 full-time equivalent patients were treated with a Sobi medicine, delivering on Sobi’s mission to deliver therapies for people

    EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

    Sobi® (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indication extension application for Tryngolza® (olezarsen) for the treatment of adult patients with severe hypertriglyceridemia (sHTG) ≥880 mg/dL (≥10 mmol/L). Patients with elevated triglyceride levels have substantially higher risks of all-cause mortality, atherosclerotic cardiovascular events, and acute pancreatitis[1].   The submission is supported by results from the pivotal Phase 3 CORE and CORE2 studies 

    Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

    The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the “Meeting”), to be held on Wednesday, 6 May 2026 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Meeting also by postal voting. Right to participate and registration (A) Participation at the meeting venue A person who wishes to attend the meeting venue in person or by proxy must · be listed as a shareholder in the

    Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma–driven sepsis presented at ISICEM

    · Primary endpoint: improvement in organ function observed in 60% of patients receiving high-dose emapalumab vs 40% with standard of care plus placebo · 28-day mortality: 40% in the high-dose emapalumab group vs 52% in the placebo group · Biomarker response: high-dose emapalumab associated with faster reduction of pro-inflammatory biomarkers linked to interferon-gamma signalling · Emapalumab was generally well tolerated Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study (NCT06694701), evaluating Gamifant® (emapalumab) in patients with

    Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

    Sobi® (STO:SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company’s strategy and outline its new mid-term outlook, aiming to achieve SEK 55bn revenue by 2030, while building a resilient platform for sustained growth beyond 2030. Sobi aims to have an adjusted EBITA margin in the upper 30s percentage of revenue by 2030.Sobi has delivered strong and profitable growth in recent years, transforming and diversifying its portfolio and positioning the company to deliver on six major launches. Additionally, Sobi is advancing priority development

    Sobi to host a Capital Markets Day on 18 February 2026

    Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on 18 February 2026, starting at 13:00 CET. A live webcast will also be available for remote participants.The CMD will feature presentations by Guido Oelkers, CEO, and members of the Management Team. Participants will have the opportunity to hear updates on Sobi’s strategy and physician-led therapeutic area sessions, followed by a Q&A session. The CMD is expected to conclude at approximately 16:00 CET.   ·

    Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

    Swedish Orphan Biovitrum AB (publ) Sobi® (STO:SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by Sobi.Upon completion of the transaction, Sobi has acquired all outstanding shares of Arthrosi’s common stock and common stock equivalents.   Arthrosi Therapeutics is a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi’s gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently

    Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress

    Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025.Fourth Quarter 2025 •          Total revenue increased 5 per cent, 16 per cent at CER1, to SEK 7,821 M (7,436)   •         Haematology revenue increased 25 per cent at CER to SEK 5,143 M (4,487), mainly driven by strong sales of Altuvoct of SEK 1,023 M (302) and of Doptelet of SEK 1,508 M (1,147), somewhat offset by lower sales of Vonjo of SEK 327 M (416)   •         Immunology revenue increased 2 per cent at CER to SEK 2,337 M (2,564), driven by strong sales of

    Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026

    Sobi (STO:SOBI) today announced its participation at the 19th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place 3-6 February 2026 in Dublin, Ireland. At this year’s meeting, Sobi will present new haemophilia data with seven scientific abstracts, including one oral presentation highlighting three years of treatment with Altuvoct from the XTEND-ed study.These presentations underscore Sobi’s mission to deliver life-changing therapies for patients with rare and severe blood disorders.   “At EAHAD 2026, we will share long-term data from

    Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

    · Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN   · Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN for patients 12 years and older   Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor,

    Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook

    Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately SEK 28.2 B, representing approximately 15 per cent growth at constant exchange rate (CER)[1]. Adjusted EBITA margin1,[2] was approximately 40 per cent of revenues.· The main reason for the increased revenue was higher than expected Q4 sales for Doptelet, Gamifant and the Haemophilia portfolio. · The adjusted EBITA margin¹,² was increased due to the higher than expected revenue.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe